Yahoo
NasdaqGS - Nasdaq Real Time Price USD

Novavax, Inc. (NVAX)

10.08 -0.39 (-3.72%)
At close: October 30 at 4:00:01 PM EDT
10.01 -0.07 (-0.73%)
After hours: October 30 at 6:56:58 PM EDT
Trade Novavax on Coinbase
Chart Range Bar
Loading chart for NVAX

What's happening with NVAX?

39m ago
Powered by Yahoo Scout

Novavax is approaching its third-quarter report with expectations for another quarterly loss and declining revenue. At the same time, its Sanofi partnership produced a $125 million milestone paymenttied to a Phase 3 combination influenza-COVID-19 vaccine trial, strengthening the licensing-led revenue strategy.

Powered by Yahoo Scout
  • Previous Close 10.47
  • Open 10.29
  • Bid 9.44 x 3000
  • Ask 11.90 x 100
  • Day's Range 9.91 - 10.65
  • 52 Week Range 6.20 - 13.39
  • Volume 4,059,377
  • Avg. Volume 6,317,465
  • Market Cap (intraday) 1.663B
  • Beta (5Y Monthly) 2.43
  • PE Ratio (TTM) --
  • EPS (TTM) -1.58
  • Earnings Date Nov 5, 2026
  • Forward Dividend & Yield -- (0.00%)
  • 1y Target Est 14.44
  • Zacks Rating Neutral

Novavax, Inc., a biotechnology company, engages in the discovery, development, and commercialization of vaccines to prevent serious infectious diseases in the United States, Europe, and internationally. The company commercializes Nuvaxovid, a COVID-19 vaccine; and R21 Matrix-M adjuvant malaria vaccine. It has license and collaboration agreements with Sanofi, Pfizer Inc., Takeda Pharmaceutical Company Limited, and Serum Life Sciences Limited for the to develop, manufacture, and commercialize the COVID-19 vaccine. The company was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.

www.novavax.com

749

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Performance Overview

Trailing total returns as of 10/30/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

NVAX
50.00%
S&P 500 (^GSPC)
10.73%

1-Year Return

NVAX
19.57%
S&P 500 (^GSPC)
11.11%

3-Year Return

NVAX
54.60%
S&P 500 (^GSPC)
81.91%

5-Year Return

NVAX
93.23%
S&P 500 (^GSPC)
64.59%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q2 FY26
Revenue 56.7M
Earnings -53.39M
Profit Margin -94.16%

Q3

FY25

Q4

FY25

Q1

FY26

Q2

FY26

-200M
-100M
0
100M
-200.0%
-100.0%
0.0%

Analyst Insights

View More

Top Analyst

B. Riley Securities
63/100
Latest Rating
Buy

Analyst Price Targets

7.00 Low
14.44 Average
10.08 Current
25.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 10/15/2026
Analyst Citigroup
Rating Action Maintains
Rating Sell
Price Action Raises
Price Target 7 -> 8

Statistics

View More

Valuation Measures

Annual
As of 10/29/2026
  • Market Cap

    1.73B

  • Enterprise Value

    1.30B

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (current)

    --

  • Price/Sales (ttm)

    4.21

  • Price/Book (mrq)

    --

  • Enterprise Value/Revenue

    3.15

  • Enterprise Value/EBITDA

    1.72

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -59.87%

  • Return on Assets (ttm)

    -6.51%

  • Return on Equity (ttm)

    --

  • Revenue (ttm)

    413.8M

  • Net Income Avi to Common (ttm)

    -247.73M

  • Diluted EPS (ttm)

    -1.58

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    719.34M

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    153.39M

Compare

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Company Insights

Fair Value

10.08 Current

Dividend Score

0 Low
Sector Avg.
100 High

Hiring Score

0 Low
Sector Avg.
100 High

Insider Sentiment Score

0 Low
Sector Avg.
100 High

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: